Effect of genetic polymorphisms in genes encoding GST isoenzymes on BU pharmacokinetics in adult patients undergoing hematopoietic SCT

Bone Marrow Transplantation

Volumn 47, Issue 2, 2012, Pages 190-195

  Ten Brink, M H ^a   Wessels, J A ^a   Hartigh, J D ^a   Van Der Straaten, T ^a   Von Dem Borne, P A ^a   Guchelaar, H J ^a   Zwaveling, J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

BU; hematopoietic SCT; pharmacogenetics; pharmacokinetics

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLELE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; AREA UNDER THE CURVE; ARTICLE; CHRONIC GRANULOCYTIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GENE DELETION; GENE DOSAGE; GENETIC VARIABILITY; GLUTATHIONE S TRANSFERASE A1 GENE; GLUTATHIONE S TRANSFERASE M1 GENE; GLUTATHIONE S TRANSFERASE P1 GENE; GRAFT REJECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE CONDITIONING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PYROSEQUENCING; SICKLE CELL ANEMIA; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE;

EID: 84857034735     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.55     Document Type: Article

References (23)

1. Grochow L, Jones R, Brundrett R, Braine H, Chen T, Saral R et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55-61. (Pubitemid 20000799)
2. Slattery J, Clift R, Buckner C, Radich J, Storer B, Bensinger W et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997; 89: 3055-3060. (Pubitemid 27172594)
3. Andersson B, Kashyap A, Gian V, Wingard J, Fernandez H, Cagnoni P et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 2002; 8: 145-154. (Pubitemid 34285073)
4. Czerwinski M, Gibbs J, Slattery J. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos 1996; 24: 1015-1019. (Pubitemid 26314555)
5. Coles B, Morel F, Rauch C, Huber W, Yang M, Teitel C et al. Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics 2001; 11: 663-669. (Pubitemid 33078235)
6. Arand M, Muhlbauer R, Hengstler J, Jager E, Fuchs J, Winkler L et al. A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms. Anal Biochem 1996; 236: 184-186. (Pubitemid 26100747)
7. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 1993; 85: 1159-1164. (Pubitemid 23212283)
8. Kelada S, Stapleton P, Farin F, Bammler T, Eaton D, Smith-Weller T et al. Glutathione S-transferase M1, T1, and P1 polymorphisms and Parkinson's disease. Neurosci Lett 2003; 337: 5-8 (Pubitemid 36078299)
9. li-Osman F, Akande O, Antoun G, Mao J, Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 1997; 272: 10004-10012. (Pubitemid 27171673)
10. Zwaveling J, Press R, Bredius R, van Derstraaten T, den HJ, Bartelink I et al. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients. Ther Drug Monit 2008; 30: 504-510.
11. Cremers S, Schoemaker R, Bredius R, den Hartigh J, Ball L, Twiss I et al. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. Br J Clin Pharmacol 2002; 53: 386-389. (Pubitemid 34415589)
12. Cremers S, Schoemaker R, Bredius R, den HJ, Ball L, Twiss I et al. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. Br J Clin Pharmacol 2002; 53: 386-389. (Pubitemid 34415589)
13. Chow D, Bhagwatwar H, Phadungpojna S, Andersson B. Stability-indicating high-performance liquid chromatographic assay of busulfan in aqueous and plasma samples. J Chromatogr lB Biomed Sci Appl 1997; 704: 277-288. (Pubitemid 28021914)
14. Proost JH, Meijer DK. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992; 22: 155-163.
15. Zwaveling J, Bredius R, Cremers S, Ball L, Lankester A, Teepe-Twiss I et al. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant 2005; 35: 17-23. (Pubitemid 40090051)
16. Proost JH. Adaptive control of drug dosage regimens using maximum a posteriori probability Bayesian fitting. Int J Clin Pharmacol Ther 1995; 33: 531-536.
17. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267. (Pubitemid 23046384)
18. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
19. Abassi N, Vadnais B, Knutson JA, Blough DK, Kelly EJ, O'Donnell PV et al. Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients. J Clin Pharmacol 2010 (e-pub ahead of print; doi:10.1177/0091270010382915).
20. Elhasid R, Krivoy N, Rowe JM, Sprecher E, Adler L, Elkin H et al. Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation. Pediatr Blood Cancer 2010; 55: 1172-1179.
21. Kusama M, Kubota T, Matsukura Y, Matsuno K, Ogawa S, Kanda Y et al. Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan. Clin Chim Acta 2006; 368: 93-98. (Pubitemid 43776023)
22. Kim S, Lee J, Hur E, Lee J, Kim D, Lim S et al. Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011 (e-pub ahead of print; doi:10.1016/j.bbmt.2010.12.708).
23. Srivastava A, Poonkuzhali B, Shaji R, George B, Mathews V, Chandy M et al. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 2004; 104: 1574-1577. (Pubitemid 39166540)